Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)
Completed · Phase 1 · NCT04330664
Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
At a glance
- Research payments reported, 2025
- $429,024
- U.S. investigators named
- 6
- Sites paid
- 5
- Planned or actual enrollment
- 86
About the trial
- Sponsor
- Mirati Therapeutics Inc. (with Novartis)
- Tested
- MRTX849 (drug), TNO155 (drug)
- Dates
- Started 2020-04-07; completion 2025-02-24
- Results posted
- Not yet
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation.
From ClinicalTrials.gov, last updated 2025-04-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Mirati Therapeutics, Inc. reported $429,024 in research payments for this study in 2025 (6 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Edward B. Garon, MD Hematology & Oncology · Los Angeles, CA
- Misako Nagasaka, MD Hematology & Oncology · Orange, CA
- Rebecca S. Heist, MD MPH Internal Medicine · Boston, MA
- Pasi Antero Janne, MD PHD Medical Oncology · Boston, MA
- Shirish M. Gadgeel, MD Medical Oncology · Detroit, MI
- Kathryn C. Arbour, M.D. Medical Oncology · New York, NY
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Uci Health Fountain Valley $168,445
- Ronald Reagan UCLA Medical Center, CA $124,644
- Memorial Sloan-Kettering Cancer Center - Cancer $83,485
- Dana-Farber Cancer Institute $48,092
- Henry Ford Health Hospital, MI $4,358
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.